Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer
Carissa E Chu1, Sima P Porten1, Gary D Grossfeld2
1Department of Urology, University of California, San Francisco, 550 16th Street, 6th Floor, San Francisco, CA 94143, USA.
Abstract:
Due to significant risks of cancer recurrence and progression, and limited options after intravesical Bacillus Calmette Guerin (BCG) therapy, there is a critical unmet need to identify novel treatments for those patients with BCG-unresponsive bladder cancer. There is active investigation of immunotherapies which provide both biologic and clinical rationales for indoleamine-2,3- dioxygenase inhibitors in salvage therapy for non-muscle invasive bladder cancer.
Insights
Novel immunotherapies, specifically indoleamine-2,3-dioxygenase inhibitors, are being investigated as a crucial treatment for bladder cancer that does not respond to Bacillus Calmette Guerin (BCG) therapy.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Non-muscle invasive bladder cancer (NMIBC) carries significant risks of recurrence and progression.
- Limited therapeutic options exist for patients with BCG-unresponsive bladder cancer.
- Intravesical Bacillus Calmette Guerin (BCG) is a standard treatment, but a subset of patients do not respond adequately.
Purpose of the Study:
- To explore the potential of novel immunotherapies as salvage treatment for BCG-unresponsive bladder cancer.
- To investigate the biologic and clinical rationale for using indoleamine-2,3-dioxygenase (IDO) inhibitors in this patient population.
Main Methods:
- Review of current research on NMIBC treatment outcomes.
- Analysis of preclinical and clinical data supporting IDO inhibitors in bladder cancer.
- Evaluation of immunotherapy strategies for refractory bladder cancer.
Main Results:
- Active investigation into immunotherapies shows promise for BCG-unresponsive bladder cancer.
- IDO inhibitors present a strong biologic and clinical rationale for salvage therapy.
- Unmet need for effective treatments in patients progressing after BCG therapy.
Conclusions:
- Indoleamine-2,3-dioxygenase inhibitors represent a promising avenue for salvage therapy in BCG-unresponsive bladder cancer.
- Further research and clinical trials are warranted to establish the efficacy of IDO inhibitors.
- Novel immunotherapies are critical for improving outcomes in refractory NMIBC.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...